A Study of LY3164530 in Participants With Cancer

• Status: Completed
• Trial end date: 2017-03-07

Summary

The main purpose of this study is to evaluate the safety of a study drug known as LY3164530 in participants with cancer that is advanced and/or has spread to another part(s) of the body.

• Phase: Phase 1

Details

• Lead Sponsor: Eli Lilly and Company